Recent News on

Join Our Twitter Chat on NET Cancer Day

October 30, 2015

The Carcinoid Cancer Foundation is hosting "Conquering NETs/Carcinoid Cancer Misdiagnoses" Twitter Chat with Steven K. Libutti, MD on November 10, 2015, Worldwide NET Cancer Awareness Day, to help bring attention to NETs/carcinoid cancer. Read more


Webinar: Peptide Receptor Radiotherapy for Neuroendocrine Tumors

October 8, 2015

Learn more about Peptide Receptor Radionuclide Therapy (PRRT), how it works, where it is being used, and who is eligible for this treatment. Register for the free webinar on October 20 at noon, Eastern Time.  Read more  

"The Waiting Room," a Lung Carcinoid Survivor's Story

September 26, 2015

“We are survivors here, in the waiting room.” Lisa Pawlak, a lung carcinoid survivor, shares her inspiring story in the September/October 2015 issue of Coping with Cancer Magazine.  Read Lisa's article here.

Luncheon with the Experts in NYC for Carcinoid and Neuroendocrine Tumor Patients

August 16, 2015

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015. There is no charge for the luncheon thanks to the generous sponsorship of Lexicon Pharmaceuticals.  Read more

Help Us to Help You

August 13, 2015

The Carcinoid Cancer Foundation is always looking at ways of improving content and services available to people living with carcinoid cancer and other neuroendocrine tumors and we are working with a pharmaceutical partner, Ipsen, to better understand what resources, information, and support you would like to see made available at each stage of your journey. Read more

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

August 5, 2015

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. Read more

Educational Program on Neuroendocrine Tumors for Oncology Nurses

August 2, 2015

“Emerging Therapies for Neuroendocrine Tumors: New Perspectives for Oncology Nurses,” is an educational program jointly provided by the Postgraduate Institute for Medicine and the Center of Excellence Media, LLC. The program, offered through June 30, 2016, is directed toward oncology nurses and other cancer care professionals who are involved in the care of patients with neuroendocrine tumors (NETs). Read more

2015 Warner Advocacy Award: Call for Nominations

July 30, 2015

Do you know someone who is a passionate advocate for patients with neuroendocrine tumors (NETs)? Novartis Oncology and The NET Alliance are searching for an outstanding NET patient advocate to recognize and honor with the 6th Annual Warner Advocacy Award. Nominations are being accepted through 5 pm, Eastern Time, on Thursday, August 20, 2015.  Read more

Denied: Michael Farris' Journey with Insurance for Neuroendocrine Cancer Treatment

June 10, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught with difficulty. Read more

CNETS Singapore Presents New Webinar Series Featuring Neuroendocrine Cancer Experts

April 22, 2015

The Carcinoid & Neuroendocrine Tumor Society (CNETS) of Singapore is embarking on a series of webinars on various topics related to the diagnosis and treatment of neuroendocrine cancers. Read more